Today: 4 June 2026
Goldman Sachs Jumps as Dow Sets New High
4 June 2026
2 mins read

Goldman Sachs Jumps as Dow Sets New High

New York, June 4, 2026, 14:02 (EDT)

Goldman Sachs (GS) traded up nearly 4.6% Thursday afternoon, hitting $1,095.89 before pulling back to $1,088.63, up $47.61 from Wednesday’s finish. That move was enough to give the Dow Jones Industrial Average a boost as buyers came back to financial stocks.

That’s a bigger deal than just any bank-stock swing because Goldman trades at a high price and is in the Dow. The Dow works as a price-weighted index, so higher-priced stocks move the index more than cheaper ones, no matter how big the companies are; S&P Dow Jones Indices calls it a 30-stock price-weighted measure of large U.S. companies.

Stocks were mixed as the Dow set a record and the S&P 500 ticked higher, but the Nasdaq dropped, dragged down by chip stocks. Financials rose 1.8%, according to Reuters, as flows shifted away from tech and into other sectors. Dustin Thackeray, chief investment officer at Crewe Advisors, called chip stocks “due for a bit of a breather.” Reuters

Big banks traded higher. Gains in JPMorgan Chase, up 3.1%, and Morgan Stanley, up 3.6%, kept Goldman’s advance from looking like an outlier. The moves pointed to buyers adding risk in Wall Street banks after financials had been under pressure in the prior session.

Dealmaking is also in focus. SpaceX put its IPO price at $135 a share, targeting $75 billion in new funds and a $1.75 trillion valuation, Reuters said. The IPO roadshow started Thursday, with the Nasdaq listing seen for next week.

Goldman Sachs is the lead underwriter on the offering, taking the top spot in managing and selling the shares. Other banks on the deal include Morgan Stanley, BofA Securities, Citigroup and J.P. Morgan, according to Reuters. That puts Goldman in the middle of one of the year’s biggest capital-markets deals.

SpaceX’s pricing call is a double-edged sword. Analysts and investors have pointed to high valuation multiples, according to Reuters. Tim Hatt, who leads research at GSMA Intelligence, called the roughly 90-times-plus revenue multiple “high by any standard,” but also said there aren’t many clear public comps for SpaceX. Reuters

Goldman CEO David Solomon sounded a cautious tone on the economy this week. He warned that rising oil prices from the Iran conflict might fuel inflation and push consumers to change how they spend in the second half. “You’re going to see more shifts in consumer behavior,” he said. Reuters

Goldman Sachs said Gunjan Samtani, its co-chairman in India and head of the India global center, will step down at the end of 2026. According to a memo seen by Reuters, Ken Castelino and Balaji Sivasubramanian are taking over as co-heads of the tech and operations centers in the country. Goldman employs more than 8,000 people in Bengaluru and Hyderabad.

Goldman’s first quarter is still giving the stock a lift. The firm posted earnings per common share of $17.55 and an annualized return on equity of 19.8%. Return on equity tracks profit against shareholder capital.

But this earnings season also showed risks for the shares. RBC Capital Markets analyst Gerard Cassidy told investors in April that “disappointment in FICC trading”—fixed income, currencies and commodities—had weighed on the stock at that point. Goldman CEO David Solomon said investment banking business was still “incredibly robust,” but he said IPOs and sponsor activity were waiting on the right market conditions. Reuters

Goldman bulls have to watch if today’s bank rally is just relief, not the start of something bigger. Oil-fueled inflation, problems in private credit, Middle East tensions, and questions over SpaceX’s price tag could take the edge off risk. Ben Snider at Goldman Sachs Research flagged the narrow market leadership and global tensions as reasons to be cautious on U.S. stocks.

Stock Market Today

  • Quantinuum IPO Raises $1.68 Billion, Prices Shares Above Range at $60
    June 4, 2026, 2:18 PM EDT. Quantinuum, a quantum computing firm backed by Honeywell, priced its initial public offering (IPO) at $60 per share, exceeding its forecasted range of $53 to $55. The company sold 28 million shares, raising approximately $1.68 billion. This transaction highlights strong market demand for advanced quantum technology companies.

Latest articles

Goldman Sachs Jumps as Dow Sets New High

Goldman Sachs Jumps as Dow Sets New High

4 June 2026
Goldman Sachs shares surged 4.6% to $1,095.89, powering the Dow to an all-time high as investors rotated into financials; the move was amplified by Goldman’s high share price in the price-weighted Dow, while the bank’s lead role in the $75 billion SpaceX IPO and strong Q1 earnings added momentum, even as analysts flagged risks from high IPO valuations and geopolitical uncertainty.
Celsius Drops in New York After Texas Inquiry Hits Alani Nu Play

Celsius Drops in New York After Texas Inquiry Hits Alani Nu Play

4 June 2026
Celsius shares plunged 6.8% to near a 52-week low after Texas opened a probe into whether its Alani Nu drinks misled consumers about safety for minors, raising fresh legal and consumer-safety concerns just as the company relies on Alani Nu for growth and integration with PepsiCo’s distribution system.
Veru shares jump after Novo Nordisk deal draws traders

Veru shares jump after Novo Nordisk deal draws traders

4 June 2026
Veru shares soared 112% to $4.78 after announcing Novo Nordisk will supply Wegovy at no charge for Veru’s Phase 2b obesity trial, with Veru retaining global rights to enobosarm but granting Novo a right of first negotiation; analysts called the deal a “significant event” and kept $24–$25 targets, while Veru warned trial risks and reimbursement challenges remain.
CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics Jumps 12% in New York Trading

4 June 2026
CRISPR Therapeutics shares soared 11.7% to $58.15 after presenting at the Jefferies Global Healthcare Conference, with sector momentum lifting gene-editing stocks and the SPDR S&P Biotech ETF up 3.0%. Casgevy, its key sickle cell therapy, posted $43 million Q1 revenue, but a $122.9 million net loss and biotech risks mean the rally hinges on investor appetite and upcoming clinical updates.
Reddit Stock Is Running Hot Again. The Ad Bet Behind RDDT’s Sudden Jump

Reddit Stock Is Running Hot Again. The Ad Bet Behind RDDT’s Sudden Jump

4 June 2026
Reddit shares surged 6.3% to $180.19 Thursday after Loop Capital reiterated a Buy rating with a $260 target and investors responded to new automated app-ad tools; first-quarter revenue jumped 69% to $663 million, but risks remain as Reddit warns that search changes or weaker ad budgets could hurt traffic and results.
Celsius Drops in New York After Texas Inquiry Hits Alani Nu Play
Previous Story

Celsius Drops in New York After Texas Inquiry Hits Alani Nu Play

Go toTop